An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum
Editorial by Theressa Henne and Clara Saillant (UNIVIE) The Value of Health Data - Results from the CPDP Moot Court “Honoured judge, We stand in front of your Court today to seek justice and clarity on a matter that is of great concern to our society. My company has...
by Luis Bonmati, Scientific Coordinator of EUCAIM project Presentation of the European Federation for Cancer Images Introducing EUCAIM: A Pan-European Initiative The goal of EUropean Federation for CAncer IMages (EUCAIM) is to build a pan-European digital federated...
Interview with Dr. Kai Vilanova, Director MRI Clínica Girona, Coordinator Radiology, Faculty of Medicine, University of Girona. Director School of MRI-ESMRMB (IDIBGI) How can the results of the ProCAncer-I project help radiologists? What are the problems that...
By Prof Kostas Marias Hellenic Mediterranean University, Head Computational BioΜedicine Lab - FORTH Enabling AI Models Traceability through ProCAncer-I AI Model Passport Artificial intelligence (AI) has brought great economic and social prospects to human society with...
By Ana Castro Verde, Ph.D. student and research technician at Computational Clinical Imaging Group, Champalimaud Foundation Clinical Challenge: Can radical prostatectomy patients help promote a biological validation of radiomics signatures? Prostate cancer patients...
National Cancer Institute is the only specialized oncology institution in Lithuania. The Institute acts as the clinical cancer center, certified and accredited by the Organization of European Cancer Institutes. • In order to achieve our strategic objectives, we...
Established in 2016, Advantis Medical Imaging makes advanced medical imaging more accessible, user-friendly and data-driven by merging it with cloud technology. By providing AI-driven, reliable and automated MRI software solutions, Advantis is on a mission to...
Newsletter #5 Contents
An international and multidisciplinary team, led by researchers from the Champalimaud Foundation, in Lisbon, has developed an artificial intelligence algorithm that improves the reliability of prostate cancer detection based solely on magnetic resonance imaging...
Prostate cancer is the second most commonly diagnosed cancer in men. Conventional screening relies on prostate specific antigen (PSA) levels in the blood, which can indicate prostate abnormalities but lacks specificity. Clinical examination and ultrasound also have...
The ProCAncer-I project aims to revolutionize prostate cancer diagnosis and treatment through the power of artificial intelligence and advanced imaging. By creating a large, federated database of prostate MRI scans and clinical data, the project enables the...
ProCAncer-I results | Prof. Daniele Regge on clinical validation In this video, we present the results of the clinical validation of AI models that were developed during the ProCAncer-i Project. Clinical validation is a critical step to ensure that AI tools not only...